Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
about
Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture CollectionEverolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis.8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraDeptor knockdown enhances mTOR Activity and protein synthesis in myocytes and ameliorates disuse muscle atrophy.Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesAssociation of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma.Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesExploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.Temsirolimus for the treatment of mantle cell lymphoma.Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Utility of mTOR inhibition in hematologic malignancies.Emerging agents for the treatment of mantle cell lymphoma.Current and emerging new treatment strategies for mantle cell lymphoma.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.Use of mTOR inhibitors in the treatment of malignancies.Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.Control of B lymphocyte development and functions by the mTOR signaling pathways.Targeting mTOR for the treatment of B cell malignancies.Association of ribosomal protein S6 kinase 1 with cellular radiosensitivity of non-small lung cancer.Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.Epoxyeicosatrienoic acids protect cardiac cells during starvation by modulating an autophagic response.Novel treatment for mantle cell lymphoma including therapy-resistant tumor by NF-κB and mTOR dual-targeting approach.RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine.Novel agents in indolent lymphomas.The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells.Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
P2860
Q27913808-0B85087F-2BB1-45A7-841E-C2C6EFB160AEQ33413598-DF9A3E8B-930F-4667-8A05-803C4480EDA6Q33421147-19BCB9E0-CFD5-4FD2-9F37-DAFE9776EBDEQ34129360-7B89C2B0-B896-4D82-81EA-24B2C6332498Q34173253-DBCE50A6-AA98-42F0-BA9B-97E2FA13F900Q34360637-58161E7F-F25C-4841-8A5A-548DCA1F86B7Q34387833-5B027DFE-3CAB-41AD-ADCE-AD2FA0678241Q34541728-41A1C736-8A6A-45EB-8113-94E00EB70A9AQ34568868-D740CB48-171E-412E-A4D6-5ADDB66BA2A4Q35286938-5CDFF41B-D901-4E6D-949C-DC10B6FC71B9Q35835983-2529D91B-CACF-469D-9F30-C2AC2E36F258Q36602853-839A24CE-2682-4219-91FC-F6C00B96C553Q36780387-B488B4E5-C92B-48AB-90A4-2FC6CCC962DDQ37028215-9ACE1FA7-2D25-4073-ACA4-9E6E33B44791Q37074284-C79A6F0F-3A8E-4097-BBEC-B6BF29BA5578Q37432231-53E710D7-14F6-4A42-954E-9B11A81AD82EQ37598141-E190DC52-020C-49C3-BBD3-21DA11921304Q37779489-43F02991-5D0E-49FC-A56D-D4DBDC868A19Q37810084-83679F9C-53AC-40C2-AD2B-A8253966C044Q37837732-DAF74A3C-63EA-43B1-9E82-54ECA53F0500Q37865381-0E71DC08-7613-42A6-B231-950986489879Q37883723-BBA687A9-8A25-465C-995E-EBC9880C56B8Q38055498-F787E5C9-2FF5-4A53-9C4F-7CC39E7663C3Q38056761-A908C556-35B9-4AB7-84ED-DC6FD31DBD04Q38150876-3CAA83CF-0122-4761-B21E-78AA8DA2BDD6Q38199196-F8F362AC-430F-46BB-BE9C-42161BF0C2E5Q38212951-862EE458-3776-4F27-9589-DF1B2C1538E9Q38674507-D5DBCE5E-8733-4884-8101-EC7D2C34C35CQ38709825-8CBBEC1B-D11B-49A9-83E2-D763DEFBD736Q38712997-AB69D7CC-C33C-4620-B8BD-ABF65C1D1B27Q38835910-38BE704A-CDE1-4DA5-A1DF-C25066DBFD5EQ38903921-3824A9B6-F274-4977-8CC4-A09ED10B4294Q39070894-128A734F-A4A4-4295-9D5B-1BFCDCFE3621Q39107517-D28F4728-3ECB-43A6-9F6C-AA651648031FQ39249148-7C594612-4571-4FDB-AFED-B4DBABC2E4C1Q39431412-7FE1EAE4-4D37-4B98-8FBE-8B93EC1C4282Q39438964-EECD5EEE-2529-4EE0-9E66-4BEC12E2EEF9Q39643259-9846ECFB-F6A4-4D7B-8ABC-8876B2CBBC93Q40789497-18C50472-94AD-404D-A8BE-6F7ADE6CCFDEQ41241688-C0822475-E2B4-4E52-8DBF-628D3940D7D8
P2860
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Activation of mammalian target ...... tosis in mantle cell lymphoma.
@en
type
label
Activation of mammalian target ...... tosis in mantle cell lymphoma.
@en
prefLabel
Activation of mammalian target ...... tosis in mantle cell lymphoma.
@en
P2093
P2860
P1476
Activation of mammalian target ...... tosis in mantle cell lymphoma.
@en
P2093
Elias Drakos
Evangelia Peponi
George Z Rassidakis
Guadalupe Reyes
L Jeffrey Medeiros
Vasiliki Leventaki
P2860
P304
P356
10.2353/AJPATH.2006.051078
P407
P577
2006-12-01T00:00:00Z